Optimer Pharmaceutic (NASDAQ: OPTR)‘s stock had its “neutral” rating reaffirmed by Zacks Investment Research in a note issued to investors on Thursday. They currently have a $14.00 price target on the stock.
Zacks’ analyst wrote, “We are encouraged by the EU approval of Dificlir as well as the strong launch of Dificid in the US. Dificid scores better than currently available treatment options on many parameters. Particularly, we believe the inclusion of superior recurrence benefits over ViroPharma’s Vancocin in the product label will provide valuable benefit and help Dificid/Dificlir sales. Dificid is the first drug to be approved in almost 25 years for the treatment of CDAD and thus targets a market with significant unmet need. However, we prefer to stay on the sidelines as Optimer is highly dependent on Dificid for its success. Following the termination of the development of Pruvel, the company hardly has anything in its pipeline. Consequently, if Dificid fails to deliver, the company will have little to fall back on. We, therefore, prefer to remain on the sidelines.”